<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Zibb.com: Genentech Incorporated (Web)</title><link>http://www.zibb.com/all/theme/cq/Genentech+Incorporated</link><atom:link rel="self" type="application/rss+xml" href="http://www.zibb.com/all/theme/cq/Genentech+Incorporated" /><description>
					Zibb. The Global business search engine.
				</description><language>
					en-US
				</language><webMaster>search@zibb.com (RB Search)</webMaster><copyright>Copyright (c) 2007 Reed Business Information. All rights reserved.</copyright><pubDate>Tue, 06 Oct 2009 14:20:17 GMT</pubDate><lastBuildDate>Tue, 06 Oct 2009 14:20:17 GMT</lastBuildDate><ttl>60</ttl><image><title>Zibb.com: Genentech Incorporated (Web)
          </title><width>88</width><height>31</height><link>http://www.zibb.com/all/theme/cq/Genentech+Incorporated</link><url>
						http://www.zibb.com/images/en/g_zibb_logo_beta.gif
					</url></image><item><title>SRDX: Management Comments on License Agreement w/Roche and Genent...
      </title><link>http://www.zibb.com/article/5572103/SRDX+Management+Comments+on+License+Agreement+w+Roche+and+Genentech</link><description>By Fain Hughes, fhughes@knobias.com SurModics, Inc. (SRDX) has signed a License and Development Agreement with Roche and Genentech, Inc., a wholly-owned member of the Roche Group. Under this agreement, Roche and Genentech have obtained an exclusive license to use SurModics' proprietary</description><guid>http://www.zibb.com/article/5572103/SRDX+Management+Comments+on+License+Agreement+w+Roche+and+Genentech</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Tue, 06 Oct 2009 14:20:17 GMT</pubDate><source url="http://www.zibb.com" /></item><item><title>Apria - resources - News</title><link>http://www.apria.com/resources/1,2725,494-863198,00.html</link><description>Genentech Inc notified doctors of 36 cases of eye inflammation among patients who received injections with the company's Avastin colon cancer drug for unapproved eye conditions.</description><guid>http://www.apria.com/resources/1,2725,494-863198,00.html</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.apria.com" /></item><item><title>Mass Spec Evolution Drives Discovery</title><link>http://www.dddmag.com/mass-spec-evolution-drives-discovery.aspx</link><description>Nano applications, mass spectrometry-based tissue imaging, and top-down proteomics are playing a role in the progress of this tool</description><guid>http://www.dddmag.com/mass-spec-evolution-drives-discovery.aspx</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.dddmag.com" /></item><item><title>[video] Late Slide Could Rule Out March Gain (at Forbes.com)</title><link>http://video.forbes.com/Friday/03288d?partner=yahootix</link><description>After Friday's triple-digit fall for the Dow Wall Street might post another losing month.</description><guid>http://video.forbes.com/Friday/03288d?partner=yahootix</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Fri, 28 Mar 2008 20:46:55 GMT</pubDate><source url="http://video.forbes.com" /></item><item><title>Tercica — Products</title><link>http://www.tercica.com/products/</link><description>Tercica was founded to bring improved treatment options to patients who suffer from endocrine and metabolic disorders. In our first five years, we collaborated with our strategic partners to launch two novel biologic products.</description><guid>http://www.tercica.com/products/</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.tercica.com" /></item><item><title>Genentech - 200002277 - New Scientist Jobs</title><link>http://www.newscientistjobs.com/jobs/promoteorganisationprofile/science--genentech-200002277.htm</link><description>Add a simple job widget to your website, web page or blog and allow your visitors to see the latest jobs from this organisation. Get the code now - it's free and there's no registration.</description><guid>http://www.newscientistjobs.com/jobs/promoteorganisationprofile/science--genentech-200002277.htm</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.newscientistjobs.com" /></item><item><title>Genentech Inc,</title><link>http://www.pharmaceutical-technology.com/projects/genentech/</link><description>News and project information on the Genentech Inc Fill and Finish Facility, Hillsboro, Oregon</description><guid>http://www.pharmaceutical-technology.com/projects/genentech/</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Wed, 07 May 2008 00:00:00 GMT</pubDate><source url="http://www.pharmaceutical-technology.com" /></item><item><title>Amgen - Media - Press Releases</title><link>http://www.abgenix.com/media/pr.jsp?year=2006</link><description>2006 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S.</description><guid>http://www.abgenix.com/media/pr.jsp?year=2006</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.abgenix.com" /></item><item><title>Protein NMR Spectroscopy - Elsevier</title><link>http://www.elsevier.com/wps/find/bookaudience.cws_home/707947/description</link><description>Principles and Practice To order this title, and for more information, click here Second Edition By John Cavanagh, North Carolina State University, Raleigh, NC 27695 Wayne J. Fairbrother, Genentech, Inc., San Francisco, CA 94080-4990 Arthur G.</description><guid>http://www.elsevier.com/wps/find/bookaudience.cws_home/707947/description</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.elsevier.com" /></item><item><title>Audio: News makes analyst bullish on Genentech</title><link>http://www.marketwatch.com/video/asset/C622D4A3-F154-40C9-874E-9CAA33990901</link><description>Charles Rotblut, senior market analyst for Zacks.com, says that the outlook for Genentech was changed dramatically on Monday, when the Federal Drug Administration gave accelerated approval for using one of the company s drugs as a first-line therapy for patients with breast cancer. The stock popped</description><guid>http://www.marketwatch.com/video/asset/C622D4A3-F154-40C9-874E-9CAA33990901</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Thu, 28 Feb 2008 13:23:09 GMT</pubDate><source url="http://www.marketwatch.com" /></item><item><title>Genentech Biotechnology Manufacturing Facility | Experience | Fai...
      </title><link>http://www.fgould.com/asia/experience/sheet/genentech-biotechnology-manufacturing-facility/</link><description>Genentech has built a commercial scale biotechnology manufacturing facility in Singapore which will be Singapore’s first microbial-based facility for biotherapeutics.</description><guid>http://www.fgould.com/asia/experience/sheet/genentech-biotechnology-manufacturing-facility/</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.fgould.com" /></item><item><title>GENENTECH, INC.</title><link>http://it.zibb.com/trademark/genentech%2c+inc./29409295</link><description>Genentech, Inc.® is a registered trademark used for Technical Consulting Services Rendered In the Field of the Life Sciences Consisting Primarily of Monitoring Clinical Studies and Supplying Rare Research Reagents and owned by Genentech, Inc..</description><guid>http://it.zibb.com/trademark/genentech%2c+inc./29409295</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://it.zibb.com" /></item><item><title>NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Ge...
      </title><link>http://www.bio-medicine.org/medicine-technology-1/NGM-Biopharmaceuticals-Appoints-Dr--Arthur-D--Levinson--Former-Genentech-CEO--to-its-Board-of-Directors-5640-1/</link><description>...SOUTH SAN FRANCISCO Calif. Oct. 21 /- NGM Biopharmaceut...Founded in 2008 NGM has created a proprietary discovery platform and ... NGM has the attributes and values that I believe are fundamental to b... Art's accomplishments and leadership during his thirty years at</description><guid>http://www.bio-medicine.org/medicine-technology-1/NGM-Biopharmaceuticals-Appoints-Dr--Arthur-D--Levinson--Former-Genentech-CEO--to-its-Board-of-Directors-5640-1/</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Wed, 21 Oct 2009 14:15:05 GMT</pubDate><source url="http://www.bio-medicine.org" /></item><item><title>QLT Inc. - NEWS - PRESS RELEASES</title><link>http://www.qltinc.com/Qltinc/pages/pagespressdetail.cfm?PressID=353&amp;YearRange=2008&amp;InternetPageID=31</link><description>QLT ANNOUNCES INTERIM RESULTS OF RADICAL STUDY EVALUATING VISUDYNE(R) COMBINATION THERAPY MEAN VISUAL ACUITY LETTER SCORES INCREASED SIMILARLY IN ALL TREATMENT GROUPS FOR IMMEDIATE RELEASE DECEMBER 16, 2008 VANCOUVER, CANADA—QLT Inc.</description><guid>http://www.qltinc.com/Qltinc/pages/pagespressdetail.cfm?PressID=353&amp;YearRange=2008&amp;InternetPageID=31</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.qltinc.com" /></item><item><title>Video: Genentech on Google Apps by Google Apps</title><link>http://www.bitpipe.com/detail/RES/1245079371_151.html?asrc=RSS_BP_KABPMANAGEIT</link><description>Please join Todd Pierce, VP of Information Technology, Genentech, as he explains why his organization chose Google Apps. Genentech was considering replacing its data center. But thanks to cloud computing from Google, the company no longer has to execute the expensive process.</description><guid>http://www.bitpipe.com/detail/RES/1245079371_151.html?asrc=RSS_BP_KABPMANAGEIT</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.bitpipe.com" /></item><item><title>Roche - Investor Update - Innovative Roche cancer medicine Avasti...
      </title><link>http://www.roche.com/inv-update-2005-01-14</link><description>Roche will now make Avastin available across Europe within the next few weeks and expects it to be accessible to physicians and patients early in the year.</description><guid>http://www.roche.com/inv-update-2005-01-14</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.roche.com" /></item><item><title>Burrill &amp; Company</title><link>http://www.interphex.com/images/100026/2008_PDFs/Keynote_Burrill.pdf</link><description>Publications (biotech book, newsletters, special purpose publications [stem cells, personalized medicine, aging etc.], The Journal of Life Sciences, web‐ based intelligence reports) Conferences Headcount: 60+ professionals and staff 44 Burrill &amp; Company U.S.</description><guid>http://www.interphex.com/images/100026/2008_PDFs/Keynote_Burrill.pdf</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.interphex.com" /></item><item><title>Efalizumab (marketed as Raptiva) Information</title><link>http://www.fda.gov/cder/drug/infopage/efalizumab/default.htm</link><description>FDA has been informed by Genentech, Inc., the sponsor of Raptiva (efalizumab), of their decision to initiate a voluntary withdrawal of Raptiva. The voluntary withdrawal will occur in phases over the next several months.</description><guid>http://www.fda.gov/cder/drug/infopage/efalizumab/default.htm</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Wed, 08 Apr 2009 22:15:00 GMT</pubDate><source url="http://www.fda.gov" /></item><item><title>Bienvenue chez Ypsomed - Genentech</title><link>http://www.ypsomed.de/cf/342.html</link><description>Accueil Pays ⁄ de | en | fr Contacts Plan du site Conditions d´utilisation Mention d´impression Existing Products Existing Products Injection Devices &amp; Partners Amylin Pharmaceuticals inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Genentech Merck Serono International S.A. Nycomed / NPS</description><guid>http://www.ypsomed.de/cf/342.html</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.ypsomed.de" /></item><item><title>[video] 3 Stocks I Saw On TV (at TheStreet.com)</title><link>http://www.thestreet.com/_yahoo/video/strategysession/10407761.html?cm_ven=YAHOO&amp;amp;cm_cat=FREE&amp;amp;cm_ite=NA</link><description>Dan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money. Today's stocks include Genentech, DSW and Macy's.</description><guid>http://www.thestreet.com/_yahoo/video/strategysession/10407761.html?cm_ven=YAHOO&amp;amp;cm_cat=FREE&amp;amp;cm_ite=NA</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Fri, 14 Mar 2008 13:11:07 GMT</pubDate><source url="http://www.thestreet.com" /></item><item><title>Committees | ISPE</title><link>http://www.ispe.org/page.ww?section=San+Francisco+Bay+Area+Chapter&amp;name=Committees</link><description>© 2008 International Society for Pharmaceutical Engineering. All rights reserved.</description><guid>http://www.ispe.org/page.ww?section=San+Francisco+Bay+Area+Chapter&amp;name=Committees</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.ispe.org" /></item><item><title>Latest Headlines</title><link>http://www.hopkinskimmelcancercenter.org/index.cfm/cID/1684/mpage/item.cfm/itemID/1108</link><description>One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage. Initial results of the drug trial, conducted at Johns Hopkins (Baltimore), the Karmanos Cancer Center (Detroit) and the Translational Genomics Research Institute (Scottsdale, Ariz.</description><guid>http://www.hopkinskimmelcancercenter.org/index.cfm/cID/1684/mpage/item.cfm/itemID/1108</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.hopkinskimmelcancercenter.org" /></item><item><title>Genentech: Research: Marc Tessier-Lavigne</title><link>http://www.gene.com/gene/research/sci-profiles/research/t-lavigne/</link><description>"I joined Genentech in 2003 as senior vice president, Research Drug Discovery. In this role, I oversee our research efforts in Oncology, as well as our nascent efforts in new therapeutic areas, including Tissue Growth and Repair, Neuroscience and Metabolism.</description><guid>http://www.gene.com/gene/research/sci-profiles/research/t-lavigne/</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.gene.com" /></item><item><title>Genentech Puts Words In the Mouths of Congress Members</title><link>http://politics.slashdot.org/story/09/11/15/1939218/Genentech-Puts-Words-In-the-Mouths-of-Congress-Members?from=rss&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Slashdot%2Fslashdot+%28Slashdot%29</link><description>theodp writes "In the official record of the historic House debate on overhauling health care, the speeches of many lawmakers echo with remarkable similarities. Often, that was no accident. Statements by more than a dozen lawmakers were ghostwritten by Washington lobbyists working for Genentech.</description><guid>http://politics.slashdot.org/story/09/11/15/1939218/Genentech-Puts-Words-In-the-Mouths-of-Congress-Members?from=rss&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Slashdot%2Fslashdot+%28Slashdot%29</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate>Sun, 15 Nov 2009 21:52:00 GMT</pubDate><source url="http://politics.slashdot.org" /></item><item><title>Roche makes lowered, hostile bid for Genentech - Forbes.com</title><link>http://www.forbes.com/feeds/ap/2009/01/30/ap5990599.html</link><description>The $86.50-per-share offer, $2.50 less than an offer rejected in July, sparked some concern from analysts that key personnel at the biotech pioneer could leave, depending on any potential deal.</description><guid>http://www.forbes.com/feeds/ap/2009/01/30/ap5990599.html</guid><category domain="http://www.zibb.com">Genentech Incorporated</category><pubDate /><source url="http://www.forbes.com" /></item></channel></rss>